A woman kneels to help a young girl with her coat in an emergent, softly lit entryway near a door and wooden bench. Light filters in from outside, creating a warm and cozy atmosphere.

PREPAREDNESS TODAY, SAFER TOMORROW.

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

A man in a pink sweater stands next to a whiteboard with handwritten notes, looking upward with a thoughtful expression as if considering emergent ideas. The writing on the board is partially blurred and difficult to read.

At Emergent, our mission is to protect and save lives.

View our 2024 Annual Report

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.
Read More

Emergent BioSolutions Reports First Quarter 2026 Financial Results

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2026.
Read More

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in adults determined to be at high risk for mpox infection.
Read More
READ ALL NEWS